J.P. Morgan analyst Anupam Rama has maintained their bullish stance on NBIX stock, giving a Buy rating on May 6.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Anupam Rama has given his Buy rating due to a combination of factors that highlight Neurocrine’s potential for growth. The recent performance of Ingrezza, despite seasonal challenges, has been promising with a notable increase in new patient starts, driven by an expanded sales force and improved formulary access. This positive trend is expected to continue, with the company anticipating a rebound in the second quarter and further growth acceleration in the latter half of 2025.
Additionally, the launch of Crenessity is seen as a significant driver for Neurocrine’s stock, with initial patient uptake showing encouraging signs, particularly among pediatric and adolescent groups. The transition of patients from pivotal extension studies to commercial therapy further supports this outlook. Anupam Rama’s valuation model suggests that the combined value of Ingrezza, Crenessity, and cash positions the stock at a favorable price level, reinforcing the Buy recommendation based on the long-term potential of these products and the company’s underappreciated pipeline.
In another report released on May 6, Evercore ISI also reiterated a Buy rating on the stock with a $190.00 price target.
Based on the recent corporate insider activity of 117 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NBIX in relation to earlier this year.